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Abstract
Introduction: Genetic variation in the apolipoprotein E (APOE) gene is associated with
Alzheimer’s disease (AD) and risk factors for cardiovascular disease (CVD).DNAmethy-
lationat APOE has been associated with altered cognition and AD. It is unclear if epige-
netic marks could be used for predicting future disease.
Methods:We assessed blood-based DNA methylation at 13 CpGs in the APOE gene in
5828 participants from theGeneration Scotland (GS) cohort. Using linearmixedmodels
regression, we examined the relationships among APOEmethylation, cognition, choles-
terol, the family history of AD and the risk for CVD.
Results: DNA methylation at two CpGs was associated with the ratio of total choles-
terol and HDL cholesterol, but not with cognition, family history of AD, or the risk of
CVD.
Discussion: APOE methylation is associated with the levels of blood cholesterol, but
there is no evidence for the utility of APOE methylation as a biomarker for predicting
AD or CVD.
K EYWORD S
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1 INTRODUCTION
1.1 The APOE gene
The apolipoprotein E (APOE) gene is located on chromosome 19, with
two single nucleotide polymorphisms (SNPs) in its fourth exon defin-
ing three alleles, 𝜀2, 𝜀3, and 𝜀4, resulting in the production of three iso-
forms of the apoE protein, apoE2, E3, and E4.1 The APOE 𝜀4 genotype
is a well-known risk factor for Alzheimer’s disease (AD)2,3 and a promi-
nent candidate in cardiovascular research.4,5 The protein is expressed
in various tissues, including the brain.6 It acts as a ligand for members
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of the low-density lipoprotein (LDL) receptor family and is involved
in the clearance of lipoproteins and cholesterol from the circulatory
system.7,8
APOE exhibits an allele-specific association with risk of AD. Pos-
session of the 𝜀4-allele confers an increased risk, while the 𝜀2-allele
is protective.2 The isoforms of apoE differ in their binding affinity
for lipoproteins and LDL receptors, and differentially influence lev-
els of serum cholesterol.9 The E2 variant reduces the levels of total
and LDL cholesterol, while the E4 variant raises them.6 However,
the connection between APOE and cardiovascular disease (CVD) is
less robust. While there is some evidence for an increased risk of
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CVD-related death in carriers of the 𝜀4-allele,1 this has not always
been observed.10
1.2 APOEmethylation in AD and CVD
Epigenetic modifications have been associated with many human
disorders.11 DNA methylation (DNAm) is most commonly observed
as the addition of a methyl group to the 5-position of cytosine in
the context of a cytosine-guanine dinucleotide (CpG12). Many studies
have found a link between AD and DNAm.12,13 Candidate gene stud-
ies for APOE have shown that DNAm in this gene is associated with
dementia14-17 with neuritic amyloid plaque burden,18 and with cogni-
tive ability.19
Associations have been suggested between epigenetic mechanisms
and risk factors for cardiovascular disease.20-23 A recent systematic
review identified 34 candidate gene studies on DNAm in CVD.4
However, few studies have exploredmodifications specifically inAPOE,
and there have been some conflicting results: while Karlsson et al.15
found no evidence for differences in APOE DNAm in blood between
patients with CVD and healthy controls, Ji et al.24 reported APOE
hypermethylation in the blood of patients with coronary heart disease
compared to controls. No AD- or CVD-related associations were
reported in the EWAS catalogue25; for cg14123992, cg04406254,
cg05501958, and cg21879725, associations with other traits were
reported (Table S1 in supporting information).
To help clarify this role of APOE, we use data fromGeneration Scot-
land (GS), a large population-based cohort, the size of which is several
times greater than samples in previous studies, providing a robust anal-
ysis of APOE DNAm and cognitive and vascular health. We included
both AD and CVD in our analysis for the following reasons: First, APOE
is both highly relevant to the genetics of AD, as well as of importance
to cardiovascular health due to its function of clearing lipoproteins and
cholesterol fromtheblood.7,8 Second, the stateof current knowledge is
relatively limited for APOE DNAm in AD and for APOE DNAm in CVD.
Third, CVD and cardiovascular risk factors strongly influence the risk
of AD and are a relevant research goal in the context of AD.
We characterize blood-based DNAm in the promoter region, 2nd
and 3rd exons and introns, and 4th exon of the APOE gene, and explore
associations among APOE DNAm and a variety of markers of cogni-
tive function, AD, vascular health, and CVD. Due to the importance
of developing new clinical biomarkers for health outcomes before the
onset of disease (the neuropathological hallmarks of dementia start to
appear decades prior to onset), we restrict our sample to ages between
30 and 65 years.
2 METHODS
2.1 The sample
GS26,27 is a family-based cohort of more than 22,000 individuals from
Scotland (aged 18 to 99 years) that were genotyped and extensively
RESEARCH INCONTEXT
1. Based on a review of the primary literature, and on
recent reviews and meta-analyses, associations have
been reported between DNAm in the apolipoprotein E
(APOE) gene andboth cognitive function and cardiovascu-
lar health. However, these have been from smaller studies
(n≤ 1076). Here, we further explore these associations in
a very large cohort with 5828 participants.
2. Our findings do not support the utility of APOE DNAm
in blood as a biomarker to predict the future risks
of Alzheimer’s disease (AD) and cardiovascular disease.
However, the findings suggest a potential association
betweenAPOEDNAmand the levels of blood cholesterol.
3. Longitudinal research on changes in DNAm is required to
elucidate the exact timing of epigenetic changes as they
relate to cognition and AD. Additionally, replication and
mechanistic studies on the observed association between
APOEDNAm and blood cholesterol are needed.
phenotyped during the baseline assessment between the years 2006
and 2011. Blood-based genome-wide DNAmwere generated in 9551
individuals as part of the substudy Stratifying Resilience and Depres-
sion Longitudinally (STRADL28). All participants provided informed
consent.
2.2 DNAMethylation and APOEmeasurements
DNAm in peripheral blood samples was profiled in two analysis sets
(Set 1: n = 5087 in 2017 and Set 2: n = 4450 in 2019), using the
Illumina HumanMethylationEPIC BeadChip as described previously.29
Briefly, low quality samples, probes with low detection rates, and par-
ticipants for which the predicted sex did not match the recorded sex
were excluded (seeMethods S1 in supporting information).
We removed related participants from Set 1 using a genetically
determined relationship cut-off of >0.05 (GCTA GREML30) to reduce
the potential influence of shared genetics on the findings. The partici-
pants in Set 2 were unrelated to each other and to those in Set 1. We
restricted the analysis to CpGs located on chromosome 19 between
45,409,039 and 45,412,650 bp, which corresponded to the region
encompassing the APOE gene (UCSC GRCh37/hg19 genome build).
To restrict the age of our sample, we removed participants younger
than 30 years and older than 65 years. After combining the two sets,
our final sample consisted of a total of 13 CpGs in 5828 participants
(Figure S1 in supporting information).
APOE haplotype status was determined using Taqman technology
at the Clinical Research Facility,Western General Hospital, Edinburgh.
Based on the identity of the nucleotides at SNP positions rs429358
and rs7412, participants with the 𝜀3/𝜀3 haplotype were classified as
𝜀3 carriers, participants with the 𝜀2/𝜀2 and 𝜀2/𝜀3 haplotypes were
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F IGURE 1 Structure of the apolipoprotein E (APOE) locus and the location of CpGs (A), and correlations among CpGs in the APOE gene (B).A:
The top panel shows the location of APOE on the chromosome, the second panel indicates the location on APOE in kb, the third panel shows the
structure of APOE, with exon regions thickened; the asterisks denote the locations of SNPs rs429358 and rs 7412 that confer the APOE genotype
classified as 𝜀2 carriers, and participantswith the 𝜀3/𝜀4 and 𝜀4/𝜀4 hap-
lotypes were classified as 𝜀4 carriers. The 126 participants (2.2%) with
the 𝜀2/𝜀4 genotype were not included in analyses in which APOE car-
rier status was implemented as a variable.
2.3 Characterization of APOEmethylation
We examined the DNAm status of 13 CpGs in the APOE gene (Fig-
ure 1A). Twelve CpGs exhibited similar DNAm levels to those previ-
ously described (Table S215,16,22 in supporting information), whereas
one of them (cg20051876, which is unique to the Illumina EPIC array)
had not been reported before. Based on the Illumina-annotated loca-
tions of the CpGs on the chromosome, their relative distances to
each other, and their DNAm levels, the CpGs were classified into
three groups: hypermethylated (each site >50% mean DNAm) and
lying in the promoter region (region 1: cg20051876, cg14123992,
cg04406254), hypomethylated (each site<50%meanDNAm)and lying
in the region encompassing the first two exons and introns (region 2:
cg26190885, cg12049787, cg08955609, cg18768621, cg19514613,
cg06750524), and hypermethylated and lying in the 4th exon (region
3: cg16471933, cg05501958, cg18799241, cg21879725).
2.4 Cognitive variables
Four measures of cognitive function27 were evaluated: (1) the Wech-
sler digit symbol test as a measure of the speed of information pro-
cessing, (2) the letter-based (C, F, L) phonemic verbal fluency test as a
measure of executive function, (3) the Mill Hill Vocabulary test (com-
bined junior and senior synonyms) as a measure of crystallized ability,
and (4) theWechsler immediate anddelayedLogicalMemory tests (one
story) as a measure of verbal declarative memory. Participants with a
zero value were judged as resulting from non-participation and were
recorded as missing. Ameasure of global cognitive function (cognitive-
g) was derived by applying principal component analysis (PCA) to the
four cognitivemeasures,with cognitive-g defined as the first unrotated
principal component. This factor explained 44% of the total variance
from all four cognitive measures, with loading values ranging between
0.47 and 0.53.
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2.5 Approximations for the risk of AD and of CVD
When completing the questionnaires, participants had reported on the
presenceof “AD”and “heart disease” for themselves and for their family
members.Only three participants reported havingAD, and 203partici-
pants (3.5%) reported having CVD.We therefore created approximate
measures of risk that were based on reports by participants about
these illnesses for close relatives (parents, siblings, and grandparents).
For both AD and CVD, each relative was assigned either 0 or 1 (0:
absence of the disorder, 1: presence of the disorder) based on the
report of the participant. To derive each risk measure, we calculated
the weighted sums of family records for each participant as follows:
risk = 0.5 × (mother + father + sister + brother) + 0.25
× (either grandparent)
The choiceofweights used for a given familymemberwasbasedonkin-
ship/relatedness between that relative and the participant. The partic-
ipants that self-reported as having AD or CVDwere excluded from the
models that included the risk ofADor the risk ofCVDas predictor vari-
ables, respectively. Due to a lownumber of relativeswithADand a con-
sequential skew in the distribution of AD risk, AD riskwas transformed
into a categorical variableADclass (low risk: no close relativeswithAD,
n = 4854; high risk: at least one close relative with AD, n = 974). Using
this approach, we were able to estimate the risk for each disorder for
every participant in the study.
2.6 Covariates
For alcohol consumption, we did not include participants that have quit
drinking (n = 373) or whose answers relating to recent alcohol con-
sumption according to their own assessment did not correspond to
their usual drinking pattern (n = 1557). Information on smoking was
processed as described previously31; we did not include participants
that havequit smoking (n=673). The sample sizes for the fully adjusted
models (see below) thus depended on the included covariates with
missing values. Smoking was assessed in pack years and alcohol con-
sumption in units per week. Activity levels were recorded in minutes
per week; two different versions of the questionnaire were used in the
study,with eachparticipant completing only oneof them.We therefore
combined the two versions so that the responses by all participants
were on the same scale (seeMethods S2 in supporting information).
2.7 Statistical analysis
For all numerical variables, outliers—defined as scores beyond four
interquartile ranges from themedian—were excluded. For the analyses
exploring effects on DNAm as an outcome, linear mixed models were
used; for analyses exploring effects onADclass as an outcome, logistic-
regressionmodels were used.
Each model was run twice: First as a basic adjusted model that
included the variable(s) as defined in the hypothesis as predictors, and
cell counts, processing batch, and analysis set as covariates. Next, a
fully adjusted model was run that included additional covariates (sex,
smoking, alcohol consumption, education, deprivation index, and—in
some models—physical activity, heart rate, body mass index [BMI],
APOE genotype; seeMethods S3 in supporting information).
The predictor-specific covariates used in the fully adjusted model
varied according to the predictor variable of the model and, when-
ever possible, corresponded with previous studies.15,22 Both the basic
and the fully adjusted model included as covariates the batch in which
the samples of a given participant were processed on the array (fit-
ted as a random effect on the intercept) and the estimated propor-
tions ofCD8+ andCD4+T-cells, natural killer cells, B cells,monocytes,
and granulocytes. Cell composition correction controls for the fact that
DNAmpatterns can be confounded by the heterogeneity of cells in the
tissue used for analysis.32
The threshold for statistical significance was Bonferroni-corrected
for each CpG. All continuous variables (except the variable age when
used as a predictor) were transformed to have a mean of 0 and a stan-
dard deviation of 1. When the predictor was a categorical variable,
analysis of variance was performed, comparing the model of interest
with the samemodel excluding the predictor variable.
All statistical analyses were performed in R.
3 RESULTS
3.1 Sample characteristics
Among the 5828 participants, 3399 (58.3%) were female and 2429
(41.7%) were male. The age range was 30 to 65 years and the mean
age was 52.7 years (Table 1). APOE genotype frequencies were
comparable to those described previously for the British population
(Table 1).10,33DNAmmeasures resembled previous reports19 andmost
CpGs appeared normally distributed upon visual inspection (Figure
S2 in supporting information). Correlations between DNAm levels in
blood (this study) and brain tissue (publicly available datasets) for the
13 CpGs in this study ranged from –0.30 to 0.51 for the whole brain
(IMAGE-CpG: https://han-lab.org/methylation/default/imageCpG,34
last accessedOctober 13, 2019), from–0.26 to0.40 forBrodmannarea
20 (BECon: https://redgar598.shinyapps.io/BECon/,35 last accessed
October 13, 2019), and from –0.21 to 0.20 for the entorhinal cortex
(https://epigenetics.essex.ac.uk/bloodbrain/,36 last accessed October
13, 2019), with most CpGs exhibiting low correlations between brain
and bloodDNAm (Table S2).
3.2 Associations between CpGs
The correlations in DNAm for all pairwise combinations between
the 13 CpGs ranged from –0.49 to 0.78, with a mean absolute
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TABLE 1 Descriptive statistics and frequencies of genotypes and
alleles/carriers in the sample
Trait Mean
a
SD
b
Age 53.0
a
14.0
a
Years in education
c
4.0
a
3.0
a
Deprivation quintile
d
4.0
a
3.0
a
Processing speed (Wechsler
digit symbol test)
71.2 15.6
Executive function
(letter-based verbal fluency
test)
41.1 11.7
Verbal ability (Mill Hill
Vocabulary test)
30.1 4.5
Verbal declarativememory
(Wechsler logical memory
test immediate and delayed)
30.9 7.7
Heart rate (beats/min) 63.7 10.3
Ratio/quotient of total
cholesterol andHDL
cholesterol
3.7
a
1.6
a
Alcohol units per week 8.0
a
12.0
a
Trait N %
Sex (female) 3399 58.3
AD in close relatives 974 16.7
CVD in close relatives 3474 59.6
Genotype/carrier n %
𝜀2/𝜀2 31 0.5
𝜀2/𝜀3 647 11.4
𝜀2/𝜀4 126 2.2
𝜀3/𝜀3 3352 59.0
𝜀3/𝜀4 1370 24.1
𝜀4/𝜀4 156 2.7
𝜀2-carrier 678 12.2
𝜀3-carrier 3352 60.3
𝜀4-carrier 1526 27.5
aThemedian is given when appropriate.
bThe interquartile range is given when appropriate.
cA 10-grade classification-system, where 0: 0 years, 1: 1–4 years, 2: 5–9
years, 3: 10–11 years, 4: 12–13 years, 5: 14–15 years, 6: 16–17 years, 7:
18–19 years, 8: 20–21 years, 9: 22–23 years, 10:≥24 years.
dScottish Index ofMultiple Deprivation (SIMD), 2011.
Abbreviations: AD, Alzheimer’s disease; CVD, cardiovascular disease
correlation of 0.32 (Figure 1B, Table S3 in supporting information).
After correcting for multiple comparisons, 68/78 correlations were
statistically significant at P< 6.4× 10-4 (= 0.05/78), with 38 (60%) pos-
itive, and 30 (40%) negative. CpGs within a region tended to bemethy-
lated to a similar extent: all significant correlations among CpGswithin
region 1 (3/3, 100%) and within region 3 (6/6, 100%), and most of the
significant correlations amongCpGswithin region 2 (11/13, 85%)were
positive. Moreover, there was a tendency for CpGs in regions 2 and 3
to bemethylated in opposite directions:most of the significant correla-
tions (17/22, 77%) were negative. In contrast, regions 1 and 3 tended
to be methylated in the same direction, with all significant correla-
tions (12/12, 100%) positive. Most CpGs exhibited strong associations
with imputed cell proportions (estimates range: -0.371 to 0.345, with
50/65 associations significant at <7.6 × 10-4; Table S4 in supporting
information).
3.3 Association betweenDNAmethylation and
genotype
After correcting for multiple testing, there was evidence for an associ-
ation between APOE carrier status and DNAm at five CpGs in the fully
adjustedmodels: cg14123992 (𝜂2=0.003,P=3.9×10-4), cg04406254
(𝜂2 = 0.004 P = 4.0 × 10-6), cg06750524 (𝜂2 = 0.022, P = 8.6 × 10-16),
cg16471933 (𝜂2=0.014, p=2.4×10-16), and cg21879725 (𝜂2=0.003,
P = 1.3 × 10-4; Figure 2, Table S5 in supporting information). Among
these five CpGs, the CpGs from regions 1 (cg14123992, cg04406254)
correlated relatively strongly with one another (r = 0.61) and with
CpGs in region 3 (cg16471933, cg21879725; r = 0.42-0.61). The CpG
from region 2 (cg06750524) exhibited weak correlations with the
other four CpGs (–0.07-[–0.04]). This suggests only two or three inde-
pendently associated CpGs with APOE carrier status. Post-hoc testing
between the APOE groups showed that at all five CpGs the associ-
ations were due to higher DNAm levels in 𝜀4 carriers compared to
𝜀3 carriers.
3.4 Age-dependent drift in DNAmethylation
In the basic-adjusted model, 7/13 CpGs showed an association with
age after correction for multiple testing (R2 range: 4.0 × 10-5–0.03;
Table S6 in supporting information). Three CpGs remained signifi-
cant after correction for multiple testing in the fully adjusted model
(Figure 3, Table S6). Most CpGs within a region exhibited the same
direction of change with respect to aging. CpGs in the generally
hypomethylated region 2 tended to have greater DNAm with older
age, whereas CpGs in the generally hypermethylated regions 1 and
3 tended to have lower DNAm with older age. None of the CpGs in
our analyses were in a list of age-related variable methylated positions
(aVMPs37). However, the Breusch-Pagan test for heteroscedasticity
indicated non-random variation in the residuals by age for all CpGs in
both the basic and the fully adjusted models (Table S7 in supporting
information).
3.5 APOEmethylation and cognitive function
We observed no association between general cognitive ability and
DNAm in the fully adjusted regressionmodels after correction formul-
tiple testing (Table S8 in supporting information). There were associ-
ations between the individual cognitive tests and DNAm levels in the
basic but not fully adjusted regression models (Table S9 in supporting
information).
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F IGURE 2 Boxplots (left) and density plots (right) for differences in DNAm levels between groups with different apolipoprotein E (APOE)
carrier status
F IGURE 3 Relationship between age (years) and DNAm (beta-levels)
3.6 APOEmethylation and the risk of AD
To determine whether APOE carrier status was associated with AD
class (0: absence of the disorder, 1: presence of the disorder), a logis-
tic regression was run, with AD class as the outcome variable and
APOE carrier status as the predictor. The Wald Chi-squared test con-
firmed a general effect of APOE carrier status on AD class in the basic
adjusted model (𝜒2=43.1, P=4.3 × 10-10) and in the fully adjusted
model (𝜒2=32.7, P=1.0 × 10-7). The 𝜀4 allele was significantly associ-
ated with the high-risk AD class both in the basic (OR=1.66, P=1.5 ×
10-10) and fully adjustedmodels (OR=1.73,P=2.3×10-7).Weobserved
no associations between DNAm levels and AD risk in the basic or fully
adjustedmodels after correcting for multiple testing (Table S10 in sup-
porting information).
3.7 APOEmethylation and the risk of CVD
We observed no association between APOE methylation and the risk
measure of CVD (Table S11 in supporting information), nor was there
any relationship between APOE genotype and the risk measure of
CVD. However, APOE genotype was associated with the ratio/quotient
of total cholesterol and high-density lipoprotein (HDL) cholesterol
in the fully adjusted model (𝜒2=68.5, P=1.3 × 10-15). Specifically,
both the 𝜀2 and 𝜀4 carriers differed in the ratio/quotient of total
cholesterol and HDL cholesterol compared to 𝜀3 carriers in the fully
adjusted model (𝜀2: estimate=-0.22, SE=0.048, P=6.4 × 10-6; 𝜀4:
estimate=0.21, SE=0.036, P=1.2 × 10-8). The ratio of ratio/quotient
of total cholesterol and HDL cholesterol was significantly asso-
ciated with DNAm levels after correcting for multiple testing at
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F IGURE 4 Relationship between ratio/quotient of total
cholesterol and high-density lipoprotein cholesterol, and DNAm
three CpGs in the fully adjusted models: cg08955609, cg18768621,
and cg16471933 (Table S12 in supporting information). Due to the
strong association between APOE genotype and cholesterol levels,
the fully adjusted model was rerun with APOE genotype as covari-
ate; cg08955609 (estimate=−0.065, SE=0.019, P=6.7 × 10-4) and
cg18768621 (estimate=−0.059, SE=0.017, P=4.3 × 10-4) remained
statistically significant (Figure4, Table S12). The validity of CVD risk as
a risk measure for CVDwas confirmed by running a logistic regression
model, with self-reported CVD as an outcome measure and CVD risk
as a predictor variable, with covariates as in the fully adjusted model
above (OR=1.81, P=2.2 × 10-10).
4 DISCUSSION
4.1 Correlations between CpGs and age-drift in
DNAmethylation
In this study, we used DNAm and phenotypic data from a large cohort,
GS, to exploreDNAm in theAPOE gene and its associationwith risk fac-
tors for AD, CVD, and blood cholesterol.
We observed correlations among CpGs, which had been reported
before.19 Compared with Liu et al.,19 the correlations observed in our
studywere stronger andmoreof themwerenegative. In contrast to the
findings of Karlsson et al.,15 the DNAm levels of five CpGs correlated
with APOE carrier status for the different APOE alleles. This difference
may be due to the increased power of our study over that of Karlsson
et al.15
We observe associations between most CpGs and imputed propor-
tions of white blood cells. It has been suggested that relative numbers
of cell subtypes might be caused by the same regulatory perturbations
that give rise to certain phenotypes.38 We did not explore potential
associations between AD or cardiovascular risk factors, and cell pro-
portions in this study, but it represents an interesting possibility for
future research.
We replicated a finding by Ma et al.22 of age drift in DNAm in the
APOE gene: 3/13CpGs showed age-dependent changes. In each hyper-
methylated CpG, DNAm levels tended to decrease with age, while in
each hypomethylated CpG, DNAm levels tended to increase with age.
All CpGs exhibited heteroscedasticity for the change in DNAm as a
function of age, demonstrating that the drift could be due to increases
in methylomic variability with increasing age. This phenomenon—
observed for many CpGs—is commonly described in the literature. It
is thought to occur due to environmental and stochastic processes that
lead to the failure of DNAm maintenance over the course of repeated
mitosis.39
4.2 Relationships among APOEmethylation, AD,
and cognition
Neither cognition nor family history of AD were associated with APOE
methylation. This might be due to a lack of appreciable changes in
APOEmethylation before the onset of symptoms of AD.Most previous
studies that associated differential APOE methylation with AD were
conducted on tissue from patients that had either been screened
positive for cognitive dysfunction,15 or diagnosedwith AD14,16,17; only
one study19 evaluated the relationship between DNAm and cognition
in healthy participants. The epigenetic changes in APOE accompanying
AD-related cognitive decline could result from the pathophysiology
of the disorder or from adaptive responses of the organism as a result
of AD, neither of which may be present at appreciable levels in the
population studied here. Another consideration concerns the tissue
used. Foraker et al.14 used post mortem brain tissue, Karlsson et al.15
and Liu et al.19 used blood, while Shao et al.16 and Wang et al.17
used both. In fact, the latter were not able to replicate their findings
from brain tissue in blood. Blood represents an attractive medium
for identifying biomarkers for disease. Indeed, it has been reported
that patients with AD and healthy controls can be distinguished based
on gene-expression patterns in blood.40 However, the APOE gene is
differently expressed between brain tissue and blood16,17 and APOE
CpGs exhibit relatively modest correlations between blood and brain
DNAm.34-36 Thus, blood-based DNAm may exhibit AD-associated
changes that are distinct from DNAm changes in the brain or they
might appear later in the course of the disorder. Finally, while some
studies have reported AD-associated changes in APOEmethylation as
described above, little research has been done on the topic and few—if
any—replication studies have been performed to validate the effects.
Moreover, some prominent studies that investigated associations
betweenDNAmand AD across the entire genome did not report APOE
to be altered in the disorder.13,41
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4.3 Relationship between APOEmethylation and
blood cholesterol
We did not replicate the finding24 of an association between APOE
methylation and CVD; our results are in line with reports by Karlsson
et al.15 and Sharma et al.42 However, we did find a negative associ-
ation between APOE methylation and the ratio of the total to HDL
cholesterol at cg08955609 and cg18768621; a finding that—to our
knowledge—had not been reported before. However, due to the
relatively small effect size, replication in other large cohorts or meta-
analyses is required to confirm these findings. Moreover, our mea-
surements of cholesterol provide only levels of total blood cholesterol
and of HDL cholesterol. Because of this—especially considering the
opposite correlation of APOE genotypewith the concentrations of LDL
and VLDL, respectively43—it is not possible to assess the relationship
betweenDNAm and the individual components of blood cholesterol.
4.4 Limitations and future directions
The results of the present study offer additional insight into the epi-
genetics of the APOE gene and its association with relevant pheno-
types. The main strength of the study is the large sample size from
a relatively representative sample of the Scottish population. Never-
theless, we recognize several limitations. First, the measures of risk
for AD and CVD were inferred from information on participants’ rel-
atives. The rough approximation of risk underestimates the impor-
tance of environmental factors. Moreover, different participants in
our cohort have different numbers of relatives. Second, the study is
limited to (a subset of) the methylome; other important epigenetic
mechanisms that are currently less accessible to analysis at scale
might also play important roles in the studied interactions. Third, our
study is based on DNAm data from the blood, which does not nec-
essarily correspond to DNAm patterns in the brain. This might pre-
clude the identification of potential epigenetic changes prior to dis-
ease onset and allows only limited insight into underlying biological
processes. However, due to the multitude of peripheral biological pro-
cesses associated with AD, blood may be a legitimate tissue for DNAm
studies. Finally, this study adopts a candidate gene approach; while
APOE is a biologically plausible candidate for implications in AD and
CVD, genome-wide approachesmay inform on the relative importance
of APOE.
In conclusion, we showed that CpGs in theAPOE gene exhibit corre-
lationswithin and between distinct regions of the gene and thatDNAm
levels at some CpGs of the APOE gene correlate with the APOE geno-
type. Furthermore, we found an association between DNAm level at
cg8955609 and cg18768621, and blood cholesterol. We did not find
differences in the levels of APOE methylation between individuals at
low risk and individuals at high risk of developing either AD or CVD.
Future work might explore longitudinal changes in DNAm as it relates
to adverse health outcomes to circumvent the problems of the present
study and improve our understanding of the exact timing of epigenetic
changes in AD and CVD.
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